P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

• Massimo Puoti,
• Graham Foster,
• Stanley Wang,
• David Mutimer,
• Edward Gane,
• Christophe Moreno,
• Ting Tsung Chang,
• SamS Lee,
• Rui Marinho,
• Jean-Francois DuFour,
• Stanislas Pol,
• Christophe Hezode,
• Stuart C. Gordon,
• Simone I. Strasser,
• Paul J. Thuluvath,
• Ran Liu,
• Tami Pilot-Matias,
• Federico Mensa

Affiliations

Massimo Puoti

AO Ospedale Niguarda Ca Granda, Milan, Italy

Graham Foster

Queen Mary University of London, Barts Health, UK

Stanley Wang

ABBVIE, North Chicago, USA

David Mutimer

Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit, Birmingham, UK

Edward Gane

University of Auckland, New Zealand

Christophe Moreno

CUB Hôpital Erasme, Université Libre de Bruxelles, Belgium

Ting Tsung Chang

National Cheng Kung University Hospital, Tainan City, Taiwan

SamS Lee

University of Calgary, Canada

Rui Marinho

Hospital S Maria, Medical School of Lisbon, Portugal

Jean-Francois DuFour

Hepatology, University clinic for visceral surgery and medicine, Bern University Hospital, Switzerland

Stanislas Pol

Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France

Christophe Hezode

Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France

Stuart C. Gordon

Henry Ford Health System, Detriot, USA

Simone I. Strasser

Royal Prince Alfred Hospital, Sydney, Australia

Paul J. Thuluvath

Mercy Medical Center and University of Maryland School of Medicine, Baltimore, USA

Ran Liu

ABBVIE, North Chicago, USA

Tami Pilot-Matias

ABBVIE, North Chicago, USA

Federico Mensa

ABBVIE, North Chicago, USA